A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

Negative Symptoms of Schizophrenia Clinical Trial

Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.

Status Not yet recruiting

Clinical Trial Summary

This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06388551
Study type	Interventional
Source	Luye Pharma Group Ltd.
Contact	Huafang Li
Phone	+8618017311256
Email	lhlh_5@163.com
Status	Not yet recruiting
Phase	Phase 1
Start date	May 10, 2024
Completion date	March 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05985993` - Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia	N/A
Withdrawn	`NCT01234298` - SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia	Phase 3
Completed	`NCT03397134` - Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia	Phase 3
Recruiting	`NCT04620460` - Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia	N/A